Detalhe da pesquisa
1.
The role of Vertebral Augmentation Procedures in the management of vertebral compression fractures secondary to multiple myeloma.
Hematol Oncol
; 41(3): 323-334, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36440820
2.
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Br J Haematol
; 193(4): 750-760, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33650100
3.
Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma.
Eur J Nucl Med Mol Imaging
; 48(8): 2558-2565, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33469686
4.
The Association between Metabolic Syndrome and Multiple Myeloma.
Acta Haematol
; 144(1): 24-33, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-32408305
5.
Integrated slice-specific dynamic shimming for whole-body diffusion-weighted MR imaging at 1.5 T.
MAGMA
; 34(4): 513-521, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33355719
6.
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.
Blood
; 132(20): 2154-2165, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30181174
7.
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
Blood
; 132(20): 2115-2124, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30181172
8.
Guidelines for the use of imaging in the management of patients with myeloma.
Br J Haematol
; 178(3): 380-393, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28677897
9.
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
Br J Haematol
; 176(6): 908-917, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28211054
10.
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.
Br J Haematol
; 196(4): e33-e37, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34636043
11.
The management of Castleman disease.
Br J Haematol
; 195(3): 328-337, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34340261
12.
COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial.
Br J Haematol
; 192(1): e14-e16, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33222153
13.
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.
Br J Haematol
; 193(3): e19-e22, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33715154
14.
Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy.
Br J Haematol
; 190(2): e83-e86, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32438482
15.
Time to redefine Myeloma.
Br J Haematol
; 171(1): 1-10, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26221971
16.
Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning.
Biol Blood Marrow Transplant
; 20(6): 890-5, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24650678
17.
Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial).
Br J Haematol
; 185(3): 573-578, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30125960
18.
Is the revised International staging system for myeloma valid in a real world population?
Br J Haematol
; 180(3): 451-454, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27734463
19.
Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma.
Eur J Haematol
; 90(5): 420-5, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23294279
20.
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.
Lancet Haematol
; 10(2): e93-e106, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36529145